PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -700.58% and -45.96%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?